The vaccine, called Prevnar, is already approved for use in adults 50 years and older, as well as children between the ages of six weeks and 17 years.
Prevnar protects against invasive diseases caused by 13 Streptococcus pneumonia strains.
The FDA decided to expand the vaccine’s use after studying results from a late-stage trial that included adults who had not yet been vaccinated against the disease.
More articles on supply chain:
GE stakes claim on cell therapy market with Biosafe acquisition
10 costliest medical conditions
FDA panel endorses Amgen’s biosimilar version of Humira
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
